These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Zipes DP; Camm AJ; Borggrefe M; Buxton AE; Chaitman B; Fromer M; Gregoratos G; Klein G; Moss AJ; Myerburg RJ; Priori SG; Quinones MA; Roden DM; Silka MJ; Tracy C; Blanc JJ; Budaj A; Dean V; Deckers JW; Despres C; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo JL; Zamorano JL; Smith SC; Jacobs AK; Adams CD; Antman EM; Anderson JL; Hunt SA; Halperin JL; Nishimura R; Ornato JP; Page RL; Riegel B; ; ; Eur Heart J; 2006 Sep; 27(17):2099-140. PubMed ID: 16923744 [No Abstract] [Full Text] [Related]
30. [Primary prevention of sudden cardiac death]. Reek S; Geller JC; Klein HU Dtsch Med Wochenschr; 2001 Apr; 126(15):435-8. PubMed ID: 11347006 [No Abstract] [Full Text] [Related]
31. [The role of ergometric testing in the clinical evaluation of arrhythmia]. Tullio D; Valerio A Minerva Cardioangiol; 1994 Mar; 42(3):85-96. PubMed ID: 8022552 [TBL] [Abstract][Full Text] [Related]
32. The prophylactic use of anti-arrhythmic drugs in acute myocardial infarction. Chung EK Singapore Med J; 1973 Sep; 14(3):205-10. PubMed ID: 4591400 [No Abstract] [Full Text] [Related]
33. [Arrhythmia risk stratification based on etiological and anatomo-structural factors]. Disertori M; Dallafior D; Marini M Ital Heart J Suppl; 2001 Dec; 2(12):1265-9. PubMed ID: 11838346 [TBL] [Abstract][Full Text] [Related]
36. [How to evaluate the arrhythmogenic risk after myocardial infarction?]. Motté G; Slama M; Sebag C; Dinanian S; Gueniche C Arch Mal Coeur Vaiss; 1992 Nov; 85(11 Suppl):1671-6. PubMed ID: 1304140 [TBL] [Abstract][Full Text] [Related]
37. [Clinical trial of propafenone (rytmonorm) in arrhythmia of patients with ischemic heart disease)]. Dobrotvorskaia TE; Koroleva ON; Gordina OV; Marakanova AV Klin Med (Mosk); 1996; 74(3):51-3. PubMed ID: 8926706 [No Abstract] [Full Text] [Related]
38. [Recent topics on diagnosis and therapy for arrhythmia]. Horie M Nihon Naika Gakkai Zasshi; 2006 Mar; 95(3):520-3. PubMed ID: 16640085 [No Abstract] [Full Text] [Related]
39. [Electric stability of the heart after myocardial infarction: role of anti-arrhythmia agents during postinfarction]. Sadoul N; Aliot E Arch Mal Coeur Vaiss; 1992 May; 85(5 Suppl):773-80. PubMed ID: 1356328 [TBL] [Abstract][Full Text] [Related]
40. [Cardiac rhythm disorders in myocardial infarct]. Zhelnov VV; Giliarovskiĭ AK; Cherkasova NA Med Sestra; 1987 Jan; 46(1):7-10. PubMed ID: 3646454 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]